Background Behind The Tamoxifen Success

The same definitions were used both for Trifecta and SCP analyses. Patients receiving ADT at any time were not considered in the analysis, in order to exclude patients with ADT-induced erectile dysfunction (ED). Continuous data were summarised as the mean and standard deviation, or median and range, while categorical variables were summarised as frequency tables. Patients meeting Trifecta criteria at baseline were compared with those not meeting Trifecta criteria. Comparison between characteristics of the two populations was performed by the Pearson's chi square in case of categorical variables, and by the t-test or Wilcoxon-Mann�CWhitney test for continuous variables, based on the normality assumption of the distribution. Comparison of http://www.selleckchem.com/products/Nolvadex.html categorical variables based on ordinal scale was performed https://en.wikipedia.org/wiki/Chlormezanone by the Mantel�CHaenszel test per trend. Time-to-event (Trifecta failure) was calculated as the difference between the starting date of the hypo-IGRT and the time of any of the first event among urinary incontinence, loss of sexual potency and disease progression (including biochemical progression), or last known follow-up visit in case of no event. The actuarial Trifecta failure-free survival rate (probability of maintaining the Trifecta status during follow-up) was estimated by the Kaplan�CMeier approach including exclusively the patients who met Trifecta criteria at baseline. Comparison of actuarial Trifecta failure-free survival rate between subgroups was performed by the log-rank test. All variables associated to Trifecta failure at a P http://www.selleckchem.com/products/Fludarabine(Fludara).html (version 9.2 for Windows). Table?1 describes the characteristics of the 337 consecutive patients with prostate cancer treated with hypo-IGRT between August 2006 and January 2011 in our Department. All patients completed the planned treatment, and there was only limited acute and late toxicity [9, 10]. The median duration of hypo-IGRT was 38 days. Patient follow-up was updated to at least the time of last questionnaire administration, with a median (range) follow-up of 19 (1�C51) months. Baseline QLQ-C30, QLQ-PR25 and IPSS were available for 290 (86%), 282 (84%) and 300 (89%) patients, respectively. IIEF-5 was available for 275 (82%) patients, 189 (56%) when excluding those with ADT at baseline. At baseline, after the consecutive exclusion of 112, 54, 2 and 97 patients due respectively to ADT, missing questionnaires, urinary incontinence and ED, Trifecta criteria were met in 72 patients (42% of all ADT-free patients with completed questionnaires). Only this patient subgroup has been taken into consideration for further analysis in this publication (Fig.